SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is experiencing heightened volatility as market participants react to recent geopolitical rhetoric from former President Trump, particularly concerning potential tariffs and comments about Greenland, which has sparked significant uncertainty among international allies. Community sentiment reflects apprehension about these developments, fueling discussions around a potential "Sell America" trade and a noticeable shift toward safe-haven assets like gold and silver amid broader economic and geopolitical concerns.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is experiencing heightened volatility due to renewed global trade tensions, specifically concerning former President Trump's comments on Greenland and potential tariffs on European allies. The community is sharply divided, with bears anticipating a deeper market correction driven by geopolitical concerns and bond market stability, while bulls are aggressively buying dips, confident in a swift rebound and a potential policy reversal. This dynamic creates significant swings as participants debate the market's underlying strength amidst uncertainty.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. is trending amid its announced record date for a new digital token initiative, which the community is discussing as a potential catalyst for a short squeeze. This development, coupled with ongoing geopolitical narratives and commentary surrounding its figurehead, fuels significant market speculation and contributes to its high volatility.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is actively trending after reporting positive Phase 1 clinical trial data for its atopic dermatitis drug, soquelitinib, demonstrating strong efficacy and a favorable safety profile, particularly in treatment-resistant patients. The news has ignited significant community discussion around a potential short squeeze and sustained bullish momentum, with many anticipating future partnerships or a buyout. This early success in a large therapeutic market is generating considerable interest in the stock's long-term potential.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a key licensing agreement with Pfizer for its Matrix-M adjuvant technology, which the community views as a significant validation for the platform and a catalyst for potential future collaborations. Many are actively discussing the stock's high short interest, anticipating a substantial market move as the short thesis weakens. Despite this positive development, debates continue around management's overall strategy to maximize shareholder value and secure additional deals for its pipeline assets.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple (AAPL) is currently experiencing highly polarized community sentiment, with many expressing frustration over its recent price decline, perceived lack of AI innovation, and broader market weakness. However, a strong counter-narrative highlights the stock as deeply oversold with historically low RSI levels, presenting a significant "buy the dip" opportunity ahead of its anticipated strong holiday quarter earnings. Geopolitical tensions and ongoing tariff discussions are further fueling volatility and shaping investor outlook on the tech giant.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following positive regulatory developments, as the FDA requested no new trials for its ANKTIVA cancer therapy's sBLA resubmission, signaling an accelerated path to market. The community is buzzing with optimism, anticipating substantial long-term growth driven by this key de-risking event and international market opportunities, while also discussing the potential for a significant short squeeze.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is trending amid intensified geopolitical rhetoric and upcoming central bank decisions, driving speculation for a potential surge in market volatility. While some traders anticipate significant upward movement, the community largely discusses its inherent decay, making it a popular instrument for short-selling and a challenging long-term hold. This highlights the ongoing tug-of-war between event-driven fear and the structural nature of volatility products.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group (TWG) is trending following its strategic move to acquire a wine authentication and trading business, aiming to diversify its luxury product portfolio. This significant acquisition, alongside a recent public offering, has fueled intense market volatility and high trading volume, with community discussions centered on its micro-cap status and the implications of the new share issuance. Sentiment remains divided, as some investors see a rebound opportunity while others eye dilution concerns.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as its stock continues to decline significantly, despite recent reports of increased production and deliveries, and a robotaxi partnership with Uber and Nvidia. Community discussions are dominated by investor frustration over persistent share dilution, concerns about management's effectiveness, and fears of bankruptcy. Many question the company's path to profitability and the long-term commitment of its major investors amid challenging EV market conditions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Zen Upgrades Opus Genetics (NASDAQ:IRD) to Hold

Wall Street Zen upgraded Opus Genetics from a "sell" rating to a "hold" rating in a research note on Saturday...

Opus Genetics (NASDAQ:IRD) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded Opus Genetics from a "hold" rating to a "sell" rating in a research report on Saturday...

Friday 1/2 Insider Buying Report: IRD, MSIF

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. At...

Opus Genetics (NASDAQ:IRD) Director Cam Gallagher Purchases 83,000 Shares

Opus Genetics, Inc. (NASDAQ:IRD - Get Free Report) Director Cam Gallagher acquired 83,000 shares of Opus Genetics stock in a transaction on Monday, December 29th. The shares were bought at an average...

Opus Genetics, Inc. (NASDAQ:IRD) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Opus Genetics, Inc. (NASDAQ:IRD - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine ratings firms that are presently covering the company, MarketBeat...

Opus Genetics (NASDAQ:IRD) Upgraded at Wall Street Zen

Wall Street Zen upgraded Opus Genetics from a "sell" rating to a "hold" rating in a research report on Saturday...

Insider Selling: Opus Genetics (NASDAQ:IRD) Director Sells 4,000,000 Shares of Stock

Opus Genetics, Inc. (NASDAQ:IRD - Get Free Report) Director Fighting Blindness Foundation sold 4,000,000 shares of the stock in a transaction on Tuesday, December 9th. The stock was sold at an...

Equities Analysts Offer Predictions for Opus Genetics FY2025 Earnings

Opus Genetics, Inc. (NASDAQ:IRD - Free Report) - Investment analysts at Brookline Capital Management issued their FY2025 earnings per share estimates for shares of Opus Genetics in a research note...

Opus Genetics, Inc. $IRD is BIOS Capital Management LP's 2nd Largest Position

BIOS Capital Management LP lifted its stake in Opus Genetics, Inc. (NASDAQ:IRD - Free Report) by 270.1% during the 2nd quarter, according to the company in its most recent disclosure with the...

FY2025 Earnings Estimate for Opus Genetics Issued By Wedbush

Opus Genetics, Inc. (NASDAQ:IRD - Free Report) - Equities researchers at Wedbush boosted their FY2025 earnings per share estimates for Opus Genetics in a research report issued on Wednesday, November...

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

Current Price	$2.24
Prev Close	$2.10
Open	$2.07
Dividend Yield	0.00%
50-Day Moving Average	$2.06
Beta	1.03
Avg. Volume	522,811.55
PE Ratio	-1.22

52-Week High	$2.59
52-Week Low	$0.65
Market Capitalization	$144.82M
EPS (Annual)	-$2.15
Price to Book	22.71
Revenue Per Employee	$610,666.67
Enterprise Value/EBITDA	N/A

IRD
Opus Genetics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IRD News

IRDOpus Genetics Inc.